{"entity":{"id":"nct06944106","kind":"trial","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of ivonescimab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","summary":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT06944106 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 30 participants, started 2025-03-28 and due to reach its primary completion in 2026-04-28. Interventions recorded: AK112. Conditions listed: Pancreatic Cancer. Primary outcome: R0 and R1 resection rates. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed pancreatic cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06944106","url":"https://clinicaltrials.gov/study/NCT06944106"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06944106","phase":"2","setting":"A Prospective, Single-arm, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab Combined With Gemcitabine and Nab-paclitaxel (AG) Regimen as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06944106/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}